At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 131 target
Drug / intervention
PDTprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy
In Brief
A Phase 4 clinical trial evaluating PDT for Central Serous Chorioretinopathy. Completed, enrolled 131 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Serous Chorioretinopathy
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedApr 2012
Primary CompletionDec 2012
Study CompletionDec 2014
TodayJul 2026
First PostedApr 10, 2012
Enrollment StartDec 1, 2010
Primary CompletionDec 1, 2012
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.2 years ago
Interventions
PDTprocedure
30% or 50% verteporfin dose PDT was given to patients with CSC